Sign inJoin waitlistJoin the waitlist

Lakshmi Rajdev

Chief, Mount Sinai Morningside · Icahn School of Medicine at Mount Sinai

Credentials: · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present
Oncology Division · Mount Sinai Morningside
Present
Icahn School of Medicine at Mount Sinai
Present

Research

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Journal of Clinical Oncology · 2015 · 478 citations
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Systematic review or meta-analysis · Journal of Clinical Oncology · 2023 · Last of 27 authors · 194 citations
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
The Lancet Oncology · 2022 · 115 citations

Joseph Sparano
7 papers
Sanjay Goel
7 papers
Andreas Kaubisch
6 papers
Jennifer Chuy
6 papers
Manish Shah
5 papers
JB
James Berenson
4 papers
MB
Michael Broder
4 papers
SA
Santiago Aparo
4 papers
Una Hopkins
4 papers
Al Benson
3 papers
Amara Nandikolla
3 papers · 3 as a fellow
AS
Anwaar Saeed
3 papers

Clinical trials

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2027
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2018–2027
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2022
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2015–2024